Next Article in Journal
Cross-Kingdom Small RNAs among Animals, Plants and Microbes
Next Article in Special Issue
Hippo Pathway in Mammalian Adaptive Immune System
Previous Article in Journal
Insights into Inflammatory Priming of Adipose-Derived Mesenchymal Stem Cells: Validation of Extracellular Vesicles-Embedded miRNA Reference Genes as A Crucial Step for Donor Selection
Open AccessReview

The Hippo Pathway in Prostate Cancer

by 1,2 and 1,2,*
1
Queen’s Medical Research Institute, University of Edinburgh Centre for Inflammation Research, Edinburgh bioQuarter, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
2
Institute for Regeneration and Repair, University of Edinburgh, Edinburgh bioQuarter, 5 Little France Drive, Edinburgh EH16 4UU, UK
*
Author to whom correspondence should be addressed.
Cells 2019, 8(4), 370; https://doi.org/10.3390/cells8040370
Received: 19 March 2019 / Revised: 17 April 2019 / Accepted: 19 April 2019 / Published: 23 April 2019
(This article belongs to the Special Issue Disease and the Hippo Pathway: Cellular and Molecular Mechanisms)
Despite recent efforts, prostate cancer (PCa) remains one of the most common cancers in men. Currently, there is no effective treatment for castration-resistant prostate cancer (CRPC). There is, therefore, an urgent need to identify new therapeutic targets. The Hippo pathway and its downstream effectors—the transcriptional co-activators, Yes-associated protein (YAP) and its paralog, transcriptional co-activator with PDZ-binding motif (TAZ)—are foremost regulators of stem cells and cancer biology. Defective Hippo pathway signaling and YAP/TAZ hyperactivation are common across various cancers. Here, we draw on insights learned from other types of cancers and review the latest advances linking the Hippo pathway and YAP/TAZ to PCa onset and progression. We examine the regulatory interaction between Hippo-YAP/TAZ and the androgen receptor (AR), as main regulators of PCa development, and how uncontrolled expression of YAP/TAZ drives castration resistance by inducing cellular stemness. Finally, we survey the potential therapeutic targeting of the Hippo pathway and YAP/TAZ to overcome PCa. View Full-Text
Keywords: hippo pathway; YAP/TAZ; prostate cancer; castration resistance; signal cross-talk; feedback loops hippo pathway; YAP/TAZ; prostate cancer; castration resistance; signal cross-talk; feedback loops
Show Figures

Figure 1

MDPI and ACS Style

Salem, O.; Hansen, C.G. The Hippo Pathway in Prostate Cancer. Cells 2019, 8, 370. https://doi.org/10.3390/cells8040370

AMA Style

Salem O, Hansen CG. The Hippo Pathway in Prostate Cancer. Cells. 2019; 8(4):370. https://doi.org/10.3390/cells8040370

Chicago/Turabian Style

Salem, Omar; Hansen, Carsten G. 2019. "The Hippo Pathway in Prostate Cancer" Cells 8, no. 4: 370. https://doi.org/10.3390/cells8040370

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop